Combination of direct intratumoral administration of dendritic cells and irradiation induces strong systemic antitumor effect mediated by GRP94/gp96 against squamous cell carcinoma in mice

International Journal of Oncology

Volumn 31, Issue 3, 2007, Pages 509-515

  Akutsu, Yasunori ^a   Matsubara, Hisahiro ^a   Urashima, Tetsuro ^a   Komatsu, Aki ^a   Sakata, Haruhito ^a   Nishimori, Takanori ^a   Yoneyama, Yasuo ^a   Hoshino, Isamu ^a   Murakami, Kentaro ^a   Usui, Akihiro ^a   Kano, Masayuki ^a   Ochiai, Takenori ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Abscopal effect; Dendritic cell; Esophageal cancer; Head and neck cancer; Intratumoral administration; Radiation; Squamous cell carcinoma

Indexed keywords

CD3 ANTIGEN; ENDOPLASMIN; MEMBRANE PROTEIN; SARCOMA GLYCOPROTEIN GP96 REJECTION ANTIGENS; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL; ARTICLE; BIOSYNTHESIS; C3H MOUSE; CD8+ T LYMPHOCYTE; CHEMISTRY; CYTOLOGY; DENDRITIC CELL; EXPERIMENTAL NEOPLASM; FEMALE; IMMUNOLOGY; METHODOLOGY; MOUSE; MULTIMODALITY CANCER THERAPY; PHENOTYPE; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; IMMUNOTHERAPY, ADOPTIVE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C3H; NEOPLASMS, EXPERIMENTAL; PHENOTYPE; PROGNOSIS;

EID: 38449092036     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.3.509     Document Type: Article

References (48)

1. Friedman EJ: Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 8: 1765-1780, 2002.
2. Chakravarty PK, Alfieri A, Thomas EK, et al: Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res 59: 6028-6032, 1999. (Pubitemid 30035614)
3. Belli F, Testori A, Rivoltini L, et al: Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 20: 4169-4180, 2002.
4. Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis JJ and Srivastava PK: Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 88: 232-238, 2000.
5. Mazzaferro V, Coppa J, Carrabba MG, et al: Vaccination with autologous tumor-derived heat shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 9: 3235-3245, 2003.
6. Larsson M, Fonteneau JF and Bhardwaj N: Dendritic cells resurrect antigens from dead cells. Trends Immunol 22: 141-148, 2001.
7. Demaria S, Ng B, Devitt ML, et al: Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 58: 862-870, 2004. (Pubitemid 38221143)
8. Mole RH: Whole body irradiation; radiobiology or medicine? Br J Radiol 26: 234-241, 1953.
9. Zheng H, Dai J, Stoilova D and Li Z: Cell surface targeting of heat shock protein gp96 induces dendritic cell maturation and antitumor immunity. J Immunol 167: 6731-6735, 2001.
10. Binder RJ and Srivastava PK: Essential role of CD91 in representation of gp96-chaperoned peptides. Proc Natl Acad Sci USA 101: 6128-6133, 2004.
11. Binder RJ, Han DK and Srivastava PK: CD91: a receptor for heat shock protein gp96. Nat Immunol 1: 151-155, 2000.
12. Facciponte JG, Wang XY, MacDonald IJ, et al: Heat shock proteins HSP70 and GP96: structural insights. Cancer Immunol Immunother 55: 339-346, 2006.
13. Vabulas RM, Braedel S, Hilf N, et al: The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem 277: 20847-20853, 2002.
14. Khurana D, Martin EA, Kasperbauer JL, et al: Characterization of a spontaneously arising murine squamous cell carcinoma (SCC VII) as a prerequisite for head and neck cancer immunotherapy. Head Neck 23: 899-906, 2001. (Pubitemid 32862295)
15. Lutz MB, Kukutsch N, Ogilvie AL, et al: An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223: 77-92, 1999.
16. Kawano T, Cui J, Koezuka Y, et al: Natural killer-like non-specific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci USA 95: 5690-5693, 1998.
17. Baker-LePain JC, Sarzotti M, Fields TA, Li CY and Nicchitta CV: GRP94 (gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression. J Exp Med 196: 1447-1459, 2002.
18. Ohba K, Omagari K, Nakamura T, et al: Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut 43: 575-577, 1998.
19. Camphausen K, Moses MA, Menard C, et al: Radiation abscopal antitumor effect is mediated through p53. Cancer Res 63: 1990-1993, 2003.
20. Nikitina EY and Gabrilovich DI: Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int J Cancer 94: 825-833, 2001.
21. Ganss R, Ryschich E, Klar E, Arnold B and Hammerling GJ: Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 62: 1462-1470, 2002. (Pubitemid 34407808)
22. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J and Hodge JW: External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 64: 4328-4337, 2004.
23. Fairburn B, Muthana M, Hopkinson K, et al: Analysis of purified gp96 preparations from rat and mouse livers using 2-D gel electrophoresis and tandem mass spectrometry. Biochimie: 2006.
24. Sastry S and Linderoth N: Molecular mechanisms of peptide loading by the tumor rejection antigen/heat shock chaperone gp96 (GRP94). J Biol Chem 274: 12023-12035, 1999.
25. Albert ML, Sauter B and Bhardwaj N: Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392: 86-89, 1998. (Pubitemid 28150594)
26. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S and Bhardwaj N: Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191: 423-434, 2000.
27. Kotera Y, Shimizu K and Mule JJ: Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 61: 8105-8109, 2001.
28. Demine R and Walden P: Testing the role of gp96 as peptide chaperone in antigen processing. J Biol Chem 280: 17573-17578, 2005.
29. Ramirez SR, Singh-Jasuja H, Warger T, et al: Glycoprotein 96-activated dendritic cells induce a CD8-biased T cell response. Cell Stress Chaperones 10: 221-229, 2005.
30. Segal BH, Wang XY, Dennis CG, et al: Heat shock proteins as vaccine adjuvants in infections and cancer. Drug Discov Today 11: 534-540, 2006. (Pubitemid 43732542)
31. + T cell effector function. J Immunol 172: 6087-6092, 2004.
32. Laad AD, Thomas ML, Fakih AR and Chiplunkar SV: Human gamma delta T cells recognize heat shock protein-60 on oral tumor cells. Int J Cancer 80: 709-714, 1999.
33. Rivoltini L, Castelli C, Carrabba M, et al: Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. J Immunol 171: 3467-3474, 2003.
34. Wang XH, Qin Y, Hu MH and Xie Y: Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes. Cancer Immunol Immunother 54: 971-980, 2005. (Pubitemid 41187705)
35. Liu S, Wang H, Yang Z, et al: Enhancement of cancer radiation therapy by use of adenovirus-mediated secretable glucose-regulated protein 94/gp96 expression. Cancer Res 65: 9126-9131, 2005.
36. Tamura Y, Peng P, Liu K, Daou M and Srivastava PK: Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278: 117-120, 1997.
37. Ueda G, Tamura Y, Hirai I, et al: Tumor-derived heat shock protein 70-pulsed dendritic cells elicit tumor-specific cytotoxic T lymphocytes (CTLs) and tumor immunity. Cancer Sci 95: 248-253, 2004.
38. Ahmed SU, Okamoto M, Oshikawa T, et al: Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4. J Immunother 27: 432-441, 2004.
39. Tong Y, Song W and Crystal RG: Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res 61: 7530-7535, 2001. (Pubitemid 32995044)
40. Schmidt T, Ziske C, Marten A, et al: Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model. Cancer Res 63: 8962-8967, 2003.
41. Tanaka F, Yamaguchi H, Ohta M, et al: Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo. Int J Cancer 101: 265-269, 2002.
42. Teitz-Tennenbaum S, Li Q, Rynkiewicz S, et al: Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res 63: 8466-8475, 2003.
43. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG and Lord EM: Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 174: 7516-7523, 2005.
44. Kim KW, Kim SH, Shin JG, et al: Direct injection of immature dendritic cells into irradiated tumor induces efficient antitumor immunity. Int J Cancer 109: 685-690, 2004.
45. Candido KA, Shimizu K, McLaughlin JC, et al: Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents. Cancer Res 61: 228-236, 2001.
46. Triozzi PL, Khurram R, Aldrich WA, Walker MJ, Kim JA and Jaynes S: Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer 89: 2646-2654, 2000. (Pubitemid 32011610)
47. Bollschweiler E, Baldus SE, Schroder W, et al: High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas. Endoscopy 38: 149-156, 2006.
48. Mayinger B, Horner P, Jordan M, et al: Light-induced autofluorescence spectroscopy for the endoscopic detection of esophageal cancer. Gastrointest Endosc 54: 195-201, 2001.